NADH
A poor quality randomized, double-blind, placebo-controlled crossover study in 26 patients with CFS of reduced nicotinamide adenine dinucleotide NADH reported positive results in 1999. No severe adverse effects were observed related to the study drug.
The RCT had several problems with its methods and a review concluded that there is no good evidence that NADH is of benefit for CFS patients.
Read more about this topic: Chronic Fatigue Syndrome Treatment, Pharmacological Treatments